Expanding the evidence base in transplantation: More and better randomized trials, and extending the value of observational data

Transplantation

Volumn 86, Issue 1, 2008, Pages 32-35

  Craig, Jonathan C ^a,b   Webster, Angela C ^a,b   Mitchell, Andrew ^c   Irwig, Les ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c Canberra ACT   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EVIDENCE BASED MEDICINE; INTERMETHOD COMPARISON; METHODOLOGY; NONRESPONSE BIAS; NOTE; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTER; TRANSPLANTATION; EPIDEMIOLOGY; HUMAN; OBSERVATION; ORGAN TRANSPLANTATION; REPRODUCIBILITY; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); EVIDENCE-BASED MEDICINE; HUMANS; OBSERVATION; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 49849104636     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817d5095     Document Type: Note

References (56)

1. Takemato SK, Arns W, Bunnapradist S, et al. Expanding the evidence base in transplantation: The complementary roles of randomized controlled trials and outcomes research. Transplantation 2008; 86: 18.
2. CollinsR,Peto R,Gray R, etal. Large-scale randomised evidence: Trials and overviews. In: Maynard A, Chalmers I, eds. Non-random reflections on health services research. London, BMJ Books 1998, pp 197- 230.
3. Greenfield S. The state of outcome research: Are we on target? N Engl J Med 1989; 320: 1142.
4. Clinton JJ. Outcomes research - A way to improve medical practice. JAMA 1991; 266: 2057.
5. Feinstein AR. Scientific standards in epidemiologic studies of the menace of daily life. Science 1988; 242: 1257.
6. Naylor CD, Guyatt GH. Users' guides to the medical literature. X. How to use an article reporting variations in the outcomes of health services. JAMA 1996; 275: 554.
7. Editorial. Cross design synthesis: A new strategy for studying medical outcomes. Lancet 1992; 340: 944.
8. Mathews JR. Quantification and the quest for medical certainty. Princeton, New Jersey, Princeton University Press 1995.
9. MRC Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment for pulmonary tuberculosis. BMJ 1948; ii: 769.
10. Peto R, Baigent C. Trials: The next 50 years. BMJ 1998; 317: 1170.
11. Doll R. Controlled trials: The 1948 watershed. BMJ 1998; 317: 1217.
12. Wennberg JE, Barry MJ, Fowler FJ, et al. Outcomes research, PORTs, and health care reform. Ann N Y Acad Sci 1993; 703: 52.
13. Lu-Yao GL, McLerran D, Wasson J, et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993; 269: 2633.
14. Welch WP, Miller ME, Welch HG, et al. Geographic variation in expenditures for physicians' services in the United States. N Engl J Med 1993; 328: 621.
15. Frater A, Sheldon TA. The outcomes movement in the USA and the UK. In: Drummond MF, Maynard A, Wells N, eds. Purchasing and providing cost-effective health care. Edinburgh, Churchill Livingstone 1993.
16. Editorial. Databases for health care outcomes. Lancet 1989; ii: 195.
17. Marwick C. Federal agency focuses on outcomes research. JAMA 1993; 270: 164.
18. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med 2008; 5: e67.
19. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses:Areviewofsubmissionstothe Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283: 2116.
20. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267.
21. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. II. Med Stat Med 1989; 8: 441.
22. Miller JN, Colditz GA, Mosteller F. How study design affects outcomes in comparisons of therapy. II. Surg Stat Med 1989; 8: 455.
23. Pettiti DB, Perlman JA, Sidney S. Postmenopausal estrogen use and heart disease. N Engl J Med 1986; 315: 131.
24. Davey SG, Phillips AN, Neaton JD. Smoking as "independent" risk factor for suicide: Illustration of an artifact from observational epidemiology. Lancet 1992; 340: 709.
25. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7: iii, 1.
26. GrodsteinF, Manson JE, Colditz GA,et al.Aprospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933.
27. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits ofestrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321.
28. Froom P,MelamedS, Kristal-BonehE,etal. Healthy volunteer effect in industrial workers. J Clin Epidemiol 1999; 52: 731.
29. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis pa-tientsof five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121.
30. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 2007; 369: 381.
31. Strippoli GF, Manno C, Schena FP, et al. Haemoglobin and haemat-ocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev 2006;(4): CD003967; PMID: 17054191.
32. Churchill DN, Thorpe KE, Vonesh EF, et al. Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1997; 8: 965.
33. Paniagua R, Amato D, Vonesh E, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates inperitoneal dialysis: ADEMEX,a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307.
34. Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group Effect of dialysis dose and membrane flux in maintenance he-modialysis. N Engl J Med 2002; 347: 2010.
35. Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: An empirical study of 125 meta-analyses. Stat Med 2000; 19: 1707.
36. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004; 15: 411.
37. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
38. Webster A, Pankhurst T, Rinaldi F, et al. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev 2006; (2): CD004756.
39. Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclo-sporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; (4): CD003961.
40. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
41. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999; 282: 1752.
42. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA 2004; 291: 2457.
43. Zarin DA, Ide NC, Tse T, et al. Issues in the registration of clinical trials. JAMA 2007; 16: 2112.
44. Boers M, Brooks P, Simon LS, et al. OMERACT: An international initiative to improve outcome measurement in rheumatology. Clin Exp Rheumatol 2005; 23: S10.
45. Elshihabi I, Chavers B, DonaldsonL, et al. Continuing improvement in cadaver donor graft survival in North American children: The 1998 Annual Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 2000; 4: 235.
46. Gjertson DW, Cecka J. Determinants of long-term survival of pediatric kidney grafts reported to the United Organ Network for Organ Sharing kidney transplant registry. Pediatr Transplant 2001; 5: 5.
47. Tatsioni A, Bonitsis NG, Ioannidis JPA. Persistence of contradicted claims in the literature. JAMA 2007; 298: 2517.
48. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 2007; 43: 2559.
49. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks: An empirical assessment. PLoS Med 2007; 4: e79.
50. Higgins JP, LittleJ,Ioannidis JP,etal. Turning the pump handle: Evolving methods for integrating the evidence on gene-disease association. Am J Epidemiol 2007; 166: 863.
51. Seminara D, Khoury MJ, O'Brien TR, et al.; Human Genome Epidemiology Network; the Network of Investigator Networks. The emergence of networks in human genome epidemiology: Challenges and opportunities. Epidemiology 2007; 18: 1.
52. Philips AN, Davey Smith G. The design of prospective epidemiological studies: More subjects or better measurements. J Clin Epidemiol 1993; 46: 1203.
53. Papnikolau PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174: 635.
54. Ioannidis JP, Adami HO. Nested randomized trials inlarge cohorts and biobanks: Studying the health effects of lifestyle factors. Epidemiology 2008; 19: 75.
55. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311: 1356.
56. Gallagher MP, Hall B, Craig J, et al.; Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry. A randomized controlled trial of cyclospor-ine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.